| __timestamp | Alnylam Pharmaceuticals, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 50561000 | 1256834000000 |
| Thursday, January 1, 2015 | 41097000 | 1271973000000 |
| Friday, January 1, 2016 | 47159000 | 1173296000000 |
| Sunday, January 1, 2017 | 76545000 | 1274610000000 |
| Monday, January 1, 2018 | 73106000 | 1437534000000 |
| Tuesday, January 1, 2019 | 194688000 | 2201424000000 |
| Wednesday, January 1, 2020 | 414801000 | 2203504000000 |
| Friday, January 1, 2021 | 704143000 | 2462160000000 |
| Saturday, January 1, 2022 | 868601000 | 2783406000000 |
| Sunday, January 1, 2023 | 1517886000 | 2832257000000 |
| Monday, January 1, 2024 | 1924873000 | 2832257000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. This analysis delves into the gross profit trends of Takeda Pharmaceutical Company Limited and Alnylam Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Takeda's gross profit consistently soared, peaking at approximately ¥2.83 trillion in 2023, showcasing a robust growth trajectory. In contrast, Alnylam's journey reflects a dynamic rise, with a staggering 3,600% increase from 2014 to 2023, reaching around $1.52 billion. This stark contrast highlights Takeda's established market dominance and Alnylam's rapid ascent in the biotech sector. Notably, 2024 data for Alnylam is missing, indicating potential reporting delays or strategic shifts. As these companies navigate the complexities of global healthcare, their financial narratives offer valuable insights into their strategic priorities and market positioning.
Bristol-Myers Squibb Company and Takeda Pharmaceutical Company Limited: A Detailed Gross Profit Analysis
Takeda Pharmaceutical Company Limited and Incyte Corporation: A Detailed Gross Profit Analysis
Gross Profit Trends Compared: Takeda Pharmaceutical Company Limited vs Walgreens Boots Alliance, Inc.
Takeda Pharmaceutical Company Limited vs Grifols, S.A.: A Gross Profit Performance Breakdown
Who Generates Higher Gross Profit? Takeda Pharmaceutical Company Limited or Arrowhead Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited vs Vericel Corporation: A Gross Profit Performance Breakdown
Takeda Pharmaceutical Company Limited vs Supernus Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown
Gross Profit Comparison: Takeda Pharmaceutical Company Limited and Amphastar Pharmaceuticals, Inc. Trends
Gross Profit Trends Compared: Alnylam Pharmaceuticals, Inc. vs Viatris Inc.
Gross Profit Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Ascendis Pharma A/S
Alnylam Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc.: A Detailed Gross Profit Analysis
Alnylam Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.: A Detailed Gross Profit Analysis